Search

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Our Businesses

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Innovating for our business

We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Sustainable Development for Generations | Boehringer Ingelheim US

At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.

Our Partnering Approach in Animal Health

Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Research & Development

How Simulation is Changing the Game in Biotherapeutic Drug Development

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Business Resource Groups at Boehringer Ingelheim

Outlook for Partnering in Animal Health 2024

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Our Businesses

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Innovating for our business

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Sustainable Development for Generations | Boehringer Ingelheim US

Our Partnering Approach in Animal Health

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

BI increases commitments to sustainable development

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Research & Development

How Simulation is Changing the Game in Biotherapeutic Drug Development